Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Estrogen Receptor Positive Breast Cancer × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 94 Carcinoma, Renal Cell 67 Neoplasm Metastasis 41 Neoplasms 34 Neuroendocrine Tumors 31 Kidney Neoplasms 24 Recurrence 16 Prostatic Neoplasms 16 Carcinoma, Non-Small-Cell Lung 16 Tuberous Sclerosis 15 Head and Neck Neoplasms 14 Triple Negative Breast Neoplasms 13 Lymphoma, Mantle-Cell 13 Lymphoma 12 Hodgkin Disease 12 Glioblastoma 12 Colorectal Neoplasms 12 Carcinoma, Hepatocellular 12 Brain Neoplasms 12 Sarcoma 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Pancreatic Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 11 Leukemia, Lymphocytic, Chronic, B-Cell 11 Carcinoma, Neuroendocrine 10 Waldenstrom Macroglobulinemia 9 Stomach Neoplasms 9 Multiple Myeloma 9 Lymphoma, Follicular 9 Lung Neoplasms 9

Interventions

Fulvestrant 2 vistusertib 1 capivasertib 1 Transurethral Resection of Bladder 1 Hydroxychloroquine 1 Everolimus 1 Estrogens 1 Estradiol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02216786 2024-12-02

MANTA

Queen Mary University of London

Phase 2 Completed

Estrogen Receptor Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡